MMRGlobal, Inc. (fka MMRF)

[Tulaz1]

Money from Celgene, When can we expect it?

We started receiving money from Celgene in the 4th Q. A lot of people look at the biotech deal as hope off in to the future in another lifetime. That is not the case. The Celgene transaction and the licensing opportunities that we are looking at have the potential of generating significant amounts of revenues now. Very very soon. The interest in our anti-cd20 products are very very high. The worldwide interest in the research and assets that we have managed to maintain and resurrect from the vaccines trials is significant and we started generating revenues from that and the company should continue to show revenue from that in the 1st Q. I am hoping revenue from those activities will become significant in the near future. I was talking to someone yesterday and I was trying to figure out a way of describing what those assets could mean to our business. It was kind of like when we acquired Favrille somebody either realized and hoped we didn’t find it or didn’t realize and we found it that there was a $300M lottery ticket stuffed in one the back drawers. I’m not suggesting that number for any reason, but that this morning there was a group of people off the east coast that received $300M from a lottery ticket. It’s just coincidental. It is believed that the research and data that is contained in those trials has value of significant amounts. The number we quoted in the 8K with Celgene is a real number and I believe there is a high degree of likelihood we will see those numbers. As a result of that there are other companies, scientists, institutions, and universities around the world that have contacted us and have expressed interest in other aspects of the assets. We have been advised by certain individuals who think that the trial for the vaccine were redesigned that there is a possibility that we could hold assets that could ultimately create a vaccine and that the company may qualify for expedited trials if they wanted to go back and try to launch those vaccines. There are a lot of opportunities. I know associated with those assets are a very very significant amount of tax loss carry forwards and despite the complication of utilization of tax loss carry forwards in todays world I hope this company gets to use every penny of it in my lifetime. Biotech is not based into the valuation of this company and it would be nice if it would be.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=62100651